CY1113735T1 - Εμβολια ογκου - Google Patents
Εμβολια ογκουInfo
- Publication number
- CY1113735T1 CY1113735T1 CY20121101024T CY121101024T CY1113735T1 CY 1113735 T1 CY1113735 T1 CY 1113735T1 CY 20121101024 T CY20121101024 T CY 20121101024T CY 121101024 T CY121101024 T CY 121101024T CY 1113735 T1 CY1113735 T1 CY 1113735T1
- Authority
- CY
- Cyprus
- Prior art keywords
- monophosphoryl lipid
- protein
- vaccines
- volume
- volume vaccines
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title 1
- 239000002671 adjuvant Substances 0.000 abstract 2
- 229940035032 monophosphoryl lipid a Drugs 0.000 abstract 2
- 102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- 101710188053 Protein D Proteins 0.000 abstract 1
- 101710132893 Resolvase Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000002158 endotoxin Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 230000003308 immunostimulating effect Effects 0.000 abstract 1
- 229920006008 lipopolysaccharide Polymers 0.000 abstract 1
- 238000012737 microarray-based gene expression Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 abstract 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 abstract 1
- 229930182490 saponin Natural products 0.000 abstract 1
- 150000007949 saponins Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Permanent Magnet Type Synchronous Machine (AREA)
- Control Of Throttle Valves Provided In The Intake System Or In The Exhaust System (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Η παρούσα εφεύρεση παρέχει νέες συνταγοποιήσεις ανοσοενισχυτικού για χρήση με αντιγόνα καρκίνου. Το ανοσοενισχυτικό περιλαμβάνει σαπωνίνη, ανοσοδιεγερτικό ολιγονουκλεοτίδιο και λιποπολυσακχαρίδιο που επιλέγεται από Μονοφωσφορύλο Λιπίδιο Α, 3-Ο-Αποακυλιωμένο Μονοφωσφορύλο Λιπίδιο Α και Διφωσφορύλο Λιπίδιο Α. Το αντιγόνο καρκίνου επιλέγεται από HASH-1 (ASCL-1) HASH-2 (ASCL-2) και πρωτεΐνη σύντηξης της MAGE και πρωτεΐνης D.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0025573A GB0025573D0 (en) | 2000-10-18 | 2000-10-18 | Vaccine |
GB0025574A GB0025574D0 (en) | 2000-10-18 | 2000-10-18 | Vaccine |
US09/690,921 US6544518B1 (en) | 1999-04-19 | 2000-10-18 | Vaccines |
EP10170408A EP2266603B1 (en) | 2000-10-18 | 2001-10-16 | Tumour vaccines |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1113735T1 true CY1113735T1 (el) | 2016-06-22 |
Family
ID=34082077
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20081100112T CY1108526T1 (el) | 2000-10-18 | 2008-01-31 | Εμβολια εναντι καρκινων |
CY20121100147T CY1112658T1 (el) | 2000-10-18 | 2012-02-14 | Εμβολια τα οποια περιεχουν αντιγονο μαgε συνδεομενο με θραυσμα πρωτεϊνης d |
CY20121101024T CY1113735T1 (el) | 2000-10-18 | 2012-10-26 | Εμβολια ογκου |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20081100112T CY1108526T1 (el) | 2000-10-18 | 2008-01-31 | Εμβολια εναντι καρκινων |
CY20121100147T CY1112658T1 (el) | 2000-10-18 | 2012-02-14 | Εμβολια τα οποια περιεχουν αντιγονο μαgε συνδεομενο με θραυσμα πρωτεϊνης d |
Country Status (14)
Country | Link |
---|---|
US (1) | US20050019340A1 (el) |
EP (1) | EP2266603B1 (el) |
JP (1) | JP2008285487A (el) |
KR (1) | KR100831139B1 (el) |
AT (1) | ATE534401T1 (el) |
CY (3) | CY1108526T1 (el) |
DE (1) | DE60131670T2 (el) |
DK (2) | DK1889630T3 (el) |
ES (2) | ES2392943T3 (el) |
HK (3) | HK1057992A1 (el) |
IL (1) | IL155282A (el) |
PL (1) | PL211151B1 (el) |
PT (3) | PT1326638E (el) |
SI (1) | SI2266603T1 (el) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6406705B1 (en) * | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
EP1077722B1 (en) | 1998-05-22 | 2006-08-09 | Ottawa Health Research Institute | Methods and products for inducing mucosal immunity |
US20040053880A1 (en) * | 2002-07-03 | 2004-03-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7569553B2 (en) * | 2002-07-03 | 2009-08-04 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7576066B2 (en) * | 2002-07-03 | 2009-08-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7605138B2 (en) * | 2002-07-03 | 2009-10-20 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7807803B2 (en) * | 2002-07-03 | 2010-10-05 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
JP2006512927A (ja) * | 2002-12-11 | 2006-04-20 | コーリー ファーマシューティカル グループ,インコーポレイテッド | 5’cpg核酸およびその使用方法 |
WO2004087203A2 (en) * | 2003-04-02 | 2004-10-14 | Coley Pharmaceutical Group, Ltd. | Immunostimulatory nucleic acid oil-in-water formulations for topical application |
ES2395818T3 (es) * | 2004-07-13 | 2013-02-15 | Charite - Universitatsmedizin Berlin | Composición que comprende un agente farmacológicamente activo acoplado a un componente específico de célula diana, y una saponina |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3238190A (en) | 1963-10-23 | 1966-03-01 | Madaus & Co K G Fa Dr | Aescin recovery |
US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US4806350A (en) * | 1986-04-18 | 1989-02-21 | Norden Laboratories, Inc. | Vaccine formulation |
WO1988005054A1 (en) | 1987-01-07 | 1988-07-14 | Imperial Cancer Research Technology Limited | Probe |
US6222020B1 (en) | 1987-01-07 | 2001-04-24 | Imperial Cancer Research Technology Limited | Antigens derived from the core protein of the human mammary epithelial mucin |
CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
US5057540A (en) * | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US4963484A (en) | 1988-01-29 | 1990-10-16 | Dana-Farber Cancer Institute, Inc. | Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen |
US5278302A (en) | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
ES2068989T3 (es) | 1989-02-04 | 1995-05-01 | Akzo Nobel Nv | Tocoles como adyuvante en vacunas. |
JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
FR2649012B1 (fr) | 1989-07-03 | 1991-10-25 | Seppic Sa | Emulsions multiphasiques injectables |
FR2649013B1 (fr) | 1989-07-03 | 1991-10-25 | Seppic Sa | Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable |
US5256643A (en) | 1990-05-29 | 1993-10-26 | The Government Of The United States | Human cripto protein |
SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
EP0468520A3 (en) | 1990-07-27 | 1992-07-01 | Mitsui Toatsu Chemicals, Inc. | Immunostimulatory remedies containing palindromic dna sequences |
ZA929870B (en) | 1991-12-23 | 1993-08-18 | Duphar Int Res | Adjuvants |
ES2108278T3 (es) | 1992-06-25 | 1997-12-16 | Smithkline Beecham Biolog | Composicion de vacuna con coadyuvantes. |
US5786148A (en) | 1996-11-05 | 1998-07-28 | Incyte Pharmaceuticals, Inc. | Polynucleotides encoding a novel prostate-specific kallikrein |
US5801005A (en) | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
WO1994021292A1 (en) * | 1993-03-23 | 1994-09-29 | Smithkline Beecham Biologicals (S.A.) | Vaccine compositions containing 3-o deacylated monophosphoryl lipid a |
US5744144A (en) | 1993-07-30 | 1998-04-28 | University Of Pittsburgh University Patent Committee Policy And Procedures | Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof |
PT729473E (pt) | 1993-11-17 | 2001-02-28 | Deutsche Om Arzneimittel Gmbh | Dissacaridos de glucosamina metodo para a sua preparacao composicao farmaceutica contendo os mesmos e sua utilizacao |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
US5688506A (en) | 1994-01-27 | 1997-11-18 | Aphton Corp. | Immunogens against gonadotropin releasing hormone |
WO1995026204A1 (en) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
ATE328890T1 (de) | 1994-07-15 | 2006-06-15 | Univ Iowa Res Found | Immunomodulatorische oligonukleotide |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
GB9620795D0 (en) | 1996-10-05 | 1996-11-20 | Smithkline Beecham Plc | Vaccines |
US5668267A (en) | 1995-05-31 | 1997-09-16 | Washington University | Polynucleotides encoding mammaglobin, a mammary-specific breast cancer protein |
US5981215A (en) | 1995-06-06 | 1999-11-09 | Human Genome Sciences, Inc. | Human criptin growth factor |
US5666153A (en) | 1995-10-03 | 1997-09-09 | Virtual Shopping, Inc. | Retractable teleconferencing apparatus |
CA2253549C (en) | 1996-06-18 | 2005-10-25 | Alza Corporation | Device for enhancing transdermal agent delivery or sampling |
DE69733651T2 (de) | 1996-07-03 | 2006-05-18 | Eisai Co., Ltd. | Lipid a-analoge enthaltende injektionen und verfahren zu deren herstellung |
US5955306A (en) | 1996-09-17 | 1999-09-21 | Millenium Pharmaceuticals, Inc. | Genes encoding proteins that interact with the tub protein |
EP1537877A3 (en) | 1996-10-11 | 2005-08-03 | The Regents Of The University Of California | Immunostimulatory polynucleotide/immunomodulatory molecule conjugates |
US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
US6231859B1 (en) * | 1996-12-02 | 2001-05-15 | Aquila Biopharmaceuticals, Inc. | Saponin adjuvant compositions |
KR100453132B1 (ko) | 1996-12-20 | 2004-10-15 | 앨자 코포레이션 | 경피 약제 플럭스를 향상시키기 위한 장치 및 방법 |
US5840871A (en) | 1997-01-29 | 1998-11-24 | Incyte Pharmaceuticals, Inc. | Prostate-associated kallikrein |
DE69831222T2 (de) | 1997-02-25 | 2006-07-13 | Corixa Corp., Seattle | Verbindungen zur immundiagnose von prostatakrebs und deren verwendung |
JP3036686B2 (ja) | 1997-02-27 | 2000-04-24 | 政夫 高橋 | 冠状動脈のバイパス手術に用いる血管吻合部の止血保持装置 |
US6406705B1 (en) * | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
PL190237B1 (pl) | 1997-04-01 | 2005-11-30 | Corixa Corp | Kompozycja adiuwantowa, szczepionka, sposób wytwarzania kompozycji adiuwantowej oraz zastosowanie |
ZA982968B (en) | 1997-04-09 | 1998-10-27 | Corixa Corp | Compositions and methods for the treatment and diagnosis of breast cancer |
US6130043A (en) | 1997-05-02 | 2000-10-10 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the prostate |
US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
WO1998056415A1 (en) | 1997-06-11 | 1998-12-17 | Aquila Biopharmaceuticals, Inc. | Purified saponins as oral adjuvants |
GB9711990D0 (en) | 1997-06-11 | 1997-08-06 | Smithkline Beecham Biolog | Vaccine |
ATE435661T1 (de) | 1997-08-29 | 2009-07-15 | Antigenics Inc | Adjuvant qs-21 enthaltende zusammensetzungen mit polysorbate oder cyclodextrin als hilfsmittel |
GB9718901D0 (en) | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
EP1009382B1 (en) | 1997-09-05 | 2003-06-18 | GlaxoSmithKline Biologicals S.A. | Oil in water emulsions containing saponins |
CA2305643A1 (en) | 1997-09-26 | 1999-04-22 | Corixa Corporation | Murine model for human carcinoma |
WO1999027961A1 (en) | 1997-12-02 | 1999-06-10 | Powderject Vaccines, Inc. | Transdermal delivery of particulate vaccine compositions |
WO1999033869A2 (en) | 1997-12-24 | 1999-07-08 | Corixa Corporation | Compounds for immunotherapy and diagnosis of breast cancer and methods for their use |
SI1659178T1 (sl) | 1998-02-05 | 2010-07-30 | Glaxosmithkline Biolog Sa | Postopek za čiščenje ali proizvodnjo MAGE proteina |
JP2002511266A (ja) | 1998-04-15 | 2002-04-16 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | 腫瘍関連核酸及びその使用 |
EP1077722B1 (en) * | 1998-05-22 | 2006-08-09 | Ottawa Health Research Institute | Methods and products for inducing mucosal immunity |
IL140845A0 (en) | 1998-07-14 | 2002-02-10 | Corixa Corp | Compositions for therapy and diagnosis of prostate cancer |
DK1104306T3 (da) * | 1998-08-10 | 2006-05-22 | Antigenics Inc | Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf |
WO2000041949A1 (fr) | 1999-01-18 | 2000-07-20 | Earth Chemical Co., Ltd. | Dispositif generateur d'aerosol |
ES2348708T3 (es) | 1999-01-29 | 2010-12-13 | Corixa Corporation | Proteinas de fusion de her-2/neu. |
WO2000052165A2 (en) | 1999-03-04 | 2000-09-08 | Corixa Corporation | Compositions and methods for breast cancer therapy and diagnosis |
GB9905124D0 (en) * | 1999-03-05 | 1999-04-28 | Smithkline Beecham Biolog | Novel compounds |
US6558670B1 (en) * | 1999-04-19 | 2003-05-06 | Smithkline Beechman Biologicals S.A. | Vaccine adjuvants |
DK1187629T3 (da) * | 1999-04-19 | 2005-01-17 | Glaxosmithkline Biolog Sa | Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid |
WO2001002828A2 (en) * | 1999-07-07 | 2001-01-11 | Tularik Inc. | Diagnosis of cancer by detecting ash2 polypeptides or polynucleotides |
CZ303468B6 (cs) * | 2000-02-23 | 2012-10-03 | Smithkline Beecham Biologicals S. A. | Imunogenní smes a farmaceutická smes |
KR20120014054A (ko) * | 2009-05-27 | 2012-02-15 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | Casb7439 작제물 |
-
2001
- 2001-10-16 PL PL391896A patent/PL211151B1/pl unknown
- 2001-10-16 PT PT01987671T patent/PT1326638E/pt unknown
- 2001-10-16 KR KR1020037005465A patent/KR100831139B1/ko not_active IP Right Cessation
- 2001-10-16 ES ES10170408T patent/ES2392943T3/es not_active Expired - Lifetime
- 2001-10-16 ES ES07121675T patent/ES2377077T3/es not_active Expired - Lifetime
- 2001-10-16 DK DK07121675.8T patent/DK1889630T3/da active
- 2001-10-16 DE DE60131670T patent/DE60131670T2/de not_active Expired - Lifetime
- 2001-10-16 DK DK10170408.8T patent/DK2266603T3/da active
- 2001-10-16 PT PT07121675T patent/PT1889630E/pt unknown
- 2001-10-16 EP EP10170408A patent/EP2266603B1/en not_active Expired - Lifetime
- 2001-10-16 PT PT10170408T patent/PT2266603E/pt unknown
- 2001-10-16 US US10/478,188 patent/US20050019340A1/en not_active Abandoned
- 2001-10-16 AT AT07121675T patent/ATE534401T1/de active
- 2001-10-16 SI SI200131015T patent/SI2266603T1/sl unknown
-
2003
- 2003-04-08 IL IL155282A patent/IL155282A/en not_active IP Right Cessation
- 2003-12-08 HK HK03108907A patent/HK1057992A1/xx not_active IP Right Cessation
-
2008
- 2008-01-31 CY CY20081100112T patent/CY1108526T1/el unknown
- 2008-04-10 HK HK11100837.4A patent/HK1147673A1/xx not_active IP Right Cessation
- 2008-04-10 HK HK08104079.8A patent/HK1117729A1/xx not_active IP Right Cessation
- 2008-05-14 JP JP2008126888A patent/JP2008285487A/ja active Pending
-
2012
- 2012-02-14 CY CY20121100147T patent/CY1112658T1/el unknown
- 2012-10-26 CY CY20121101024T patent/CY1113735T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
CY1108526T1 (el) | 2014-04-09 |
PT2266603E (pt) | 2012-11-02 |
PL211151B1 (pl) | 2012-04-30 |
ES2377077T3 (es) | 2012-03-22 |
KR20030044015A (ko) | 2003-06-02 |
PT1889630E (pt) | 2012-02-29 |
CY1112658T1 (el) | 2016-02-10 |
PT1326638E (pt) | 2008-02-06 |
US20050019340A1 (en) | 2005-01-27 |
SI2266603T1 (sl) | 2012-12-31 |
EP2266603B1 (en) | 2012-09-12 |
HK1057992A1 (en) | 2004-04-30 |
IL155282A (en) | 2010-11-30 |
DK2266603T3 (da) | 2012-11-05 |
HK1117729A1 (en) | 2009-01-23 |
EP2266603A1 (en) | 2010-12-29 |
ES2392943T3 (es) | 2012-12-17 |
HK1147673A1 (en) | 2011-08-19 |
JP2008285487A (ja) | 2008-11-27 |
DE60131670T2 (de) | 2008-10-30 |
DE60131670D1 (de) | 2008-01-10 |
ATE534401T1 (de) | 2011-12-15 |
KR100831139B1 (ko) | 2008-05-20 |
DK1889630T3 (da) | 2012-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1113735T1 (el) | Εμβολια ογκου | |
BR9814483A (pt) | "vacina" | |
LU91778I2 (fr) | Menveo - vaccin méningococcique des groupes A,C, W135 et Y conjugué. | |
IS4518A (is) | Nýtt lyfjaform fyrir bóluefni | |
ATE315405T1 (de) | Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung | |
PT865297E (pt) | Composicoes de vacinas para administracao intranasal compreendendo quitosano e suas utilizacoes | |
DE69733020D1 (de) | Immunostimulierende oligonucleotidekonjugate | |
CY1111056T1 (el) | Εμβολιο κυστιδιου εξωτερικης μεμβρανης (omv) που περιλαμβανει πρωτεϊνες εξωτερικης μεμβρανης απο ν. meningitidis οροομαδας β | |
PT1203817E (pt) | Compostos e metodos para imunoterapia e le diagnostic de tuberculose | |
DZ2462A1 (fr) | Vaccin antigrippal. | |
BR0114786A (pt) | Composição imunogênica, método de tratamento de um paciente que sofre de, ou que é suscetìvel a, um câncer, e, uso de uma combinação de uma saponina, um oligotìdeo imunoestimulador e um antìgeno de câncer, e, método para a manufatura de uma composição | |
DE60226175D1 (de) | Mycobakterieller impfstoff | |
ATE370745T1 (de) | Verbesserte polysaccharid- und glykokonjugat- vakzine | |
GEP20053446B (en) | Adjuvant Combination Formulations | |
WO2000050073A3 (en) | Caulobacter lps immunoadjuvant | |
WO1992006113A3 (en) | Derivatives of gp160 and vaccines based on gp160 or a derivative thereof, containing an adjuvant |